|
Table of Contents 1. Analyst View
2. Research Methodology
3. Newborn Screening - An Introduction
4. Drivers and Challenges
4.1 Drivers
4.1.1 Increased Awareness Due to Government Initiatives
4.1.2 Rising Chromosomal Abnormalities in Infants
4.1.3 Funding Aiding the Growth of Newborn Screening
4.2 Challenges
4.2.1 Lack of Hospital Infrastructure Proving Dangerous for Newborns
4.2.2 Unclear Regulatory Policies
5. US Newborn Screening Market Overview
6. Market Segmentation by Technology
6.1 Introduction
6.1.1 Enzymes and Immunoassays
6.1.2 Hearing Screening
6.1.3 Tandem Mass Spectrometry
6.1.4 Pulse Oximetry
6.1.5 DNA Based Assays
6.1.6 Electrophoresis
7. Trends and Developments
7.1 Newborn Screening Test Recommended for Pompe’s Disease
7.2 Next Generation Sequencing Foraying into Newborn Screening
8. Competitive Assessment
8.1 Perkin Elmer
8.2 Waters Corporation
8.3 Natus Medical
8.4 Agilent Technologies Inc. List of Figures: Figure 5-1: Newborn Screening Test Market (Million US$), 2014 & 2020
Figure 5-2: Newborn Screening Technology Market (Million US$), 2014-2020
Figure 6-1: US Newborn Screening Market by Technology (%), 2014
Figure 6-2: Enzymes and Immunoassays Market for Newborn Screening (Million US$), 2014 & 2020
Figure 6-3: Hearing Screen Technology Market for Newborn Screening (Million US$), 2014 &2020
Figure 6-4: Tandem Mass Spectrometry Market for Newborn Screening (Million US$), 2014 & 2020
Figure 6-5: Pulse Oximetry Technology Market for Newborn Screening (Million US$), 2014 & 2020
Figure 6-6: DNA-Based Assays Market for Newborn Screening (Million US$), 2014 & 2020
Figure 6-7: Electrophoresis Market for Newborn Screening (Million US$), 2014 & 2020 List of Tables: Table 5-1: Number of Conditions Tested & Cost by States (2014)
Table 5-2: Common Misconceptions Held by the Public and the Clinical Facts
Table 8-1: Perkin Elmer - Key Financials (Million US$), 2012-2014
Table 8-2: Waters Corporation - Key Financials (Million US$), 2012-2014
Table 8-3: Natus Medical - Key Financials (Million US$), 2012-2014
Table 8-4: Agilent - Key Financials (Million US$), 2013-2015
|
현재위치 : 
